Otsuka Holdings Co., Ltd. (4578) Earnings Releases & Disclosures
| Date | Type | Title | Files |
|---|---|---|---|
| 2026-09-14 | — | Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median PFS Benefit in Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation NSCLC | |
| 2026-09-01 | Treasury Shares | Notice regarding the status of share repurchases | |
| 2026-08-13 | — | Zipalertinib Plus Chemotherapy Meets Primary PFS Endpoint in Planned Interim Analysis of Phase 3 REZILIENT3 Trial | |
| 2026-08-04 | — | Otsuka Unveils Phase3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT(sibeprenlimab-szsi) Stabilizes Kidney Function Decline in IgAN | |
| 2026-08-03 | Treasury Shares | Notice regarding the status of share repurchases | |
| 2026-07-31 | Earnings Release | Consolidated Financial Results for the Six-Month Period Ended June 30, 2026 [IFRS] | |
| 2026-07-31 | Forecast Revision | Notice Regarding Revision of Full-Year Consolidated Financial Forecast and Payment of Interim Dividend and Revision of Year-End Dividend Forecast (Inc | |
| 2026-07-28 | Forecast Revision | Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2026 |
TDnet keeps only 31 days; this site accumulates daily and cannot backfill earlier disclosures.